Koichiro Yoneyama

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Midori Shima, Hideji Hanabusa, Masashi Taki et al. · New England Journal of Medicine · 2016 · 449 citations · Full text

A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects

Naoki Uchida, Takehiko Sambe, Koichiro Yoneyama et al. · Blood · 2015 · 251 citations · Full text

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors

Midori Shima, Keiji Nogami, Sayaka Nagami et al. · Haemophilia · 2019 · 148 citations · Full text

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Midori Shima, Hideji Hanabusa, Masashi Taki et al. · Blood Advances · 2017 · 122 citations · Full text

Phase 1/2, Thrombosis, Translational Medicine +14

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A

Koichiro Yoneyama, Christophe Schmitt, Naoki Kotani et al. · Clinical Pharmacokinetics · 2017 · 77 citations · Full text